|Over a week ago|
Century Therapeutics initiated with an Outperform at SVB Leerink » 08:4707/1307/13/21
SVB Leerink analyst Daina…
SVB Leerink analyst Daina Graybosch initiated coverage of Century Therapeutics with an Outperform rating and $33 price target. The analyst believes Century Therapeutics has a cell therapy platform that could prove transformative. Foundational to its approach is dedication to allogenic, induced pluripotent stem cells and passive allo-evasion. Graybosch thinks these two elements bring the flexibility in product development necessary for success across tumor indications and care settings. Compared to other allogenic sources, the analyst believes iPSC is best suited for optimization of functionality across multiple dimensions in parallel, which will be necessary for breadth in success.
Century Therapeutics initiated with an Overweight at JPMorgan » 08:3607/1307/13/21
JPMorgan analyst Eric…
JPMorgan analyst Eric Joseph initiated coverage of Century Therapeutics with an Overweight rating and $40 price target. The analyst believes Century's induced pluripotent stem cell platform, with its novel Allo-Evasion technology, is "uniquely equipped" to address some of the challenges presented in the manufacture of donor-derived products, in particular complex genetic engineering, consistency and efficient scalability. He believes the self-renewing capacity of iPSCs could offer potential for multiple cell modifications and improved CAR cell persistency relative to other donor-derived candidates.
BofA starts Century Therapeutics at Buy with $34 price target » 07:4707/1307/13/21
As previously reported,…
As previously reported, BofA analyst Geoff Meacham initiated coverage of Century Therapeutics with a Buy rating and $34 price target. Century's platform uses induced pluripotent stem cells, or iPSCs, to develop chimeric antigen receptor-NK cells and CAR-T cells s for oncology, noted Meacham. Century is "one of just a few companies pushing the leading edge of NK cell therapy" and its platform could be "among the leaders in the gene / cell therapy space," added the analyst.
Century Therapeutics initiated with a Buy at BofA » 06:1107/1307/13/21
BofA initiated coverage…
BofA initiated coverage of Century Therapeutics with a Buy rating and $34 price target.
Century Therapeutics initiated with an Overweight at Piper Sandler » 04:4707/1307/13/21
Piper Sandler analyst…
Piper Sandler analyst Edward Tenthoff initiated coverage of Century Therapeutics (IPSC) with an Overweight rating and $38 price target. Century is developing a pipeline of differentiated iNK and iT cell therapies with four investigational new drugs over the next three years, Tenthoff tells investors in a research note. The analyst sees Fate Therapeutics (FATE) as Century's closest comp and believes there is opportunity for Century to "close the valuation gap" by advancing its cell therapies into the clinic, reporting data and signing new partnerships.
Opening Day: Moving iMage moves up on market debut » 08:1207/1007/10/21
SNTG, RNAZ, AGRI, MITQ, LDOC, DIDI, BABA, CYT, FEMY, DNAY, AMAM, TRMR, ATAI, IPSC, VERV, LYEL, ISPC, HOOD, RGCB, QNIU, CMSL, SPRK, BLND, SCAN, VTEX, GAMB, DUOL, AUTH, RXST
Shares of Moving iMage…
|Over a month ago|
Opening Day: WalkMe stock price falls following $287M IPO » 08:3406/1906/19/21
CYT, FEMY, AMAM, DNAY, TRMR, ATAI, IPSC, RERE, VERV, LYEL, ISPC, WKME, MOLN, CNVY, ALZN, FLYW, PAY, ZIP, DAWN, FIGS, OMIC, CNTA, DIDI, QNIU, RGCB, ELEV, CMSL, DNUT, YOU, GS, MS, JPM, AMZN, F, SAFO, HOOD
Backed by Insight Venture…
Century Therapeutics opens at $19.50, IPO priced at $20 per share » 12:1406/1806/18/21
Century Therapeutics is…
Century Therapeutics is developing genetically engineered, iPSC-derived iNK and iT cell products to specifically target hematologic and solid tumor cancers.
Century Therapeutics indicated to open at $20, IPO priced at $20 » 11:1806/1806/18/21
Century Therapeutics (IPSC) priced 10.55M shares at $20.00, at the top end of the $18.00-$20.00 range. JPMorgan, BofA, SVB Leerink and Piper Sandler are acting as joint book running managers for the offering. Century Therapeutics is developing genetically engineered, iPSC-derived iNK and iT cell products to specifically target hematologic and solid tumor cancers.
Century Therapeutics 10.55M share IPO priced at $20.00 » 18:1906/1706/17/21
The deal priced at top…
The deal priced at top end of $18.00-$20.00 range. JPMorgan, BofA, SVB Leerink and Piper Sandler are acting as joint book running managers for the offering.